W. Lumry

发表

Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.

J. B. West, Kimberly Poarch, W. Lumry, 2021, Clinical therapeutics.

Hereditary Angioedema: The Economics of Treatment of an Orphan Disease

W. Lumry, 2018, Front. Med..

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

William H. Yang, J. Bernstein, W. Lumry, 2018, JAMA.

Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy

W. Lumry, John T. Anderson, D. Levy, 2021, Allergy, Asthma & Clinical Immunology.

Once-daily budesonide via Turbuhaler improves symptoms in adults with persistent asthma.

W. Lumry, W. Howland, C. Banov, 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Absence of QTc Prolongation with Cetirizine in Children Aged 6 to 11 Years

W. Lumry, D. Pearlman, J. Winder, 1996 .

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

J. Church, W. Lumry, H. Schroeder, 2012, Journal of Clinical Immunology.

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

R. Lockey, R. Pawankar, W. Aberer, 2022, The World Allergy Organization journal.

US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema.

J. Bernstein, W. Lumry, P. Busse, 2020, The journal of allergy and clinical immunology. In practice.

WAO Guideline for the Management of Hereditary Angioedema

R. Lockey, R. Pawankar, W. Lumry, 2012, The World Allergy Organization journal.

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

W. Lumry, R. Shapiro, R. Wasserman, 2021, Frontiers in Immunology.

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma.

W. Lumry, J. Given, M. White, 2000, American journal of respiratory and critical care medicine.

Desloratadine therapy for symptoms associated with perennial allergic rhinitis.

W. Lumry, J. Hébert, D. Gates, 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema.

J. Bernstein, W. Lumry, J. Schranz, 2014, The journal of allergy and clinical immunology. In practice.

Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age

W. Lumry, R. Tachdjian, M. Riedl, 2022, Allergy, Asthma & Clinical Immunology.

Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler.

G. Settipane, J. Kemp, D. Bernstein, 1999, Respiratory medicine.

Consensus on treatment goals in hereditary angioedema: a global Delphi initiative.

J. Bernstein, W. Lumry, H. Farkas, 2021, The Journal of allergy and clinical immunology.

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.

J. Bousquet, S. Holgate, S. Wenzel, 2004, Chest.

Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis.

E. Meltzer, W. Lumry, W. Berger, 2006, Allergy and asthma proceedings.

Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.

J. Biedenkapp, J. Bernstein, W. Lumry, 2015, The journal of allergy and clinical immunology. In practice.

Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.

S. Wenzel, W. Lumry, F. Cox, 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.

C. Crim, W. Lumry, M. M. Conway, 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma.

T L Petty, W. Busse, T. Petty, 1998, The Journal of allergy and clinical immunology.

Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema.

W. Lumry, 2017, Immunology and allergy clinics of North America.

Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.

W. Lumry, H. Nolte, J. Hébert, 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Once-Daily Cetirizine Effective in the Treatment of Seasonal Allergic Rhinitis in Children Aged 6 to 1 Years: A Randomized, Double-Blind, Placebo-Controlled Study

W. Lumry, D. Pearlman, J. Winder, 1997, Clinical pediatrics.

Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate.

R. Dockhorn, A. van As, E. Meltzer, 1993, The Journal of allergy and clinical immunology.

Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily.

W. Lumry, B. Prenner, J. Corren, 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy

W. Lumry, D. Levy, L. Omert, 2020, Journal of infusion nursing : the official publication of the Infusion Nurses Society.

Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma

W. Lumry, G. Shapiro, J. Given, 2000 .

Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease

R. Kobayashi, C. Cunningham-Rundles, L. Forbes, 2016, Journal of Clinical Immunology.

An Otolaryngology, Neurology, Allergy, and Primary Care Consensus on Diagnosis and Treatment of Sinus Headache

M. Setzen, R. Cady, H. Levine, 2006, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis.

W. Lumry, 1999, The Journal of allergy and clinical immunology.

Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma.

K. Nolop, W. Lumry, A. Scardella, 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema-Prevalence and Relevance.

W. Lumry, I. Reese, A. Grumach, 2021, The journal of allergy and clinical immunology. In practice.

[WAO Guideline for the Management of Hereditary Angioedema].

R. Lockey, R. Pawankar, W. Lumry, 2015, Arerugi = [Allergy].

Population pharmacokinetics of subcutaneous C1‐inhibitor for prevention of attacks in patients with hereditary angioedema

P. Keith, J. Bernstein, W. Lumry, 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency.

J. Bernstein, W. Lumry, P. Busse, 2013, The journal of allergy and clinical immunology. In practice.

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.

J. Bernstein, W. Lumry, T. Craig, 2013, Allergy and asthma proceedings.

A comparison of once-daily triamcinolone acetonide aqueous and twice-daily beclomethasone dipropionate aqueous nasal sprays in the treatment of seasonal allergic rhinitis.

J. Murray, W. Lumry, F. Hampel, 2003, Allergy and asthma proceedings.

Tri-Nasal Triamcinolone Acetonide Nasal Spray 200 and 400 μg qd versus Placebo and Nasacort Triamcinolone Acetonide Nasal Aerosol 440 μg qd in Patients Suffering from Seasonal Allergic Rhinitis during the Grass Season

R. Dockhorn, P. Korenblat, W. Lumry, 1998 .

Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis.

W. Busse, D. Bernstein, W. Lumry, 1996, The Journal of allergy and clinical immunology.

The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression.

W. Lumry, M. Vernon, A. Castaldo, 2010, Allergy and asthma proceedings.

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update

R. Lockey, R. Pawankar, W. Lumry, 2018, Allergy.

Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency

J. Bernstein, W. Lumry, P. Busse, 2016, Pediatrics.

Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children.

W. Lumry, M. Davis-Lorton, M. Manning, 2013, The Journal of pediatrics.

Nano fi ltered C 1-Esterase Inhibitor for the Acute Management and Prevention of Hereditary Angioedema Attacks due to C 1-Inhibitor De fi ciency in Children

W. Lumry, M. Davis-Lorton, M. Manning, 2013 .

A consensus parameter for the evaluation and management of angioedema in the emergency department.

C. Camargo, C. Lindsell, J. Bernstein, 2014, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

Training patients for self‐administration of a new subcutaneous C1‐inhibitor concentrate for hereditary angioedema

W. Lumry, J. Chiao, L. Omert, 2018, Nursing open.

Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.

R. Lockey, J. Biedenkapp, J. Bernstein, 2017, The New England journal of medicine.

Acute and chronic desensitization of penicillin-allergic patients using oral penicillin.

H. S. Earl, W. Lumry, T. Sullivan, 1987, The Journal of allergy and clinical immunology.

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency

M. Triggiani, P. Schmid‐Grendelmeier, W. Aberer, 2016, Allergy.

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema

T. Machnig, J. Bernstein, W. Lumry, 2017, Allergy & rhinology.

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies

W. Lumry, H. Farkas, P. Busse, 2011, The World Allergy Organization journal.

Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.

J. Bernstein, W. Lumry, P. Busse, 2010, The New England journal of medicine.

Management and prevention of hereditary angioedema attacks.

W. Lumry, 2013, The American journal of managed care.

Repeat treatment of acute hereditary angioedema attacks with open‐label icatibant in the FAST‐1 trial

W. Lumry, B. Ritchie, J. Hébert, 2014, Clinical and experimental immunology.

Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial.

J. Bernstein, W. Lumry, H. Farkas, 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.

W. Lumry, P. Busse, D. Johnston, 2012, Allergy and asthma proceedings.

Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.

C. Town, W. Lumry, H. Farkas, 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

William H. Yang, P. Keith, P. Schmid‐Grendelmeier, 2010, The New England journal of medicine.

EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.

W. Lumry, M. Campion, W. Pullman, 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

William H. Yang, P. Keith, P. Kralickova, 2017, The New England journal of medicine.

Prevalence of hereditary angioedema in untested first-degree blood relatives of known subjects with hereditary angioedema.

W. Lumry, P. Busse, M. Riedl, 2015, Allergy and asthma proceedings.

Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema.

W. Lumry, P. Busse, M. Riedl, 2015, The journal of allergy and clinical immunology. In practice.

Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema.

W. Lumry, 2013, The American journal of managed care.

Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.

Lynda Schneider, W. Lumry, L. Schneider, 2007, The Journal of allergy and clinical immunology.

An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial

J. Bernstein, A. Maetzel, W. Lumry, 2023, The Lancet.

Safety of Recombinant Human C1 Esterase Inhibitor for Hereditary Angioedema Attacks During Pregnancy.

J. Bernstein, Kimberly Poarch, W. Lumry, 2019, The journal of allergy and clinical immunology. In practice.

Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3

W. Lumry, H. Farkas, T. Craig, 2015, International Archives of Allergy and Immunology.

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema

W. Aberer, W. Lumry, H. Farkas, 2021, Clinical Reviews in Allergy & Immunology.

Inhibiting plasma kallikrein for hereditary angioedema prophylaxis

R. Lockey, J. Biedenkapp, J. Bernstein, 2017 .

Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency.

W. Lumry, P. Busse, T. Craig, 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Before and after, the impact of available on-demand treatment for HAE.

J. Bernstein, W. Lumry, P. Busse, 2015, Allergy and asthma proceedings.

Hereditary angioedema: implications of treating a rare disease.

J. Bernstein, W. Lumry, M. Frank, 2012, Annals of Allergy, Asthma & Immunology.

Nanofiltered C1 Esterase Inhibitor for Treatment of Laryngeal Attacks in Patients with Hereditary Angioedema

W. Lumry, T. Craig, M. Riedl, 2013, American journal of rhinology & allergy.

Current state of hereditary angioedema management: a patient survey.

J. Bernstein, W. Lumry, P. Busse, 2015, Allergy and asthma proceedings.

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry.

T. Machnig, W. Lumry, P. Busse, 2015, The journal of allergy and clinical immunology. In practice.

Treatment of laryngeal hereditary angioedema.

W. Lumry, D. Talan, Mark Richman, 2012, The Journal of emergency medicine.

Current and emerging therapies to prevent hereditary angioedema attacks.

W. Lumry, 2018, The American journal of managed care.

Abstracts from the 10th C1-inhibitor deficiency workshop

William H. Yang, A. Szilágyi, M. Margaglione, 2017, Allergy, Asthma & Clinical Immunology.

Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study.

William H. Yang, Moshe Y. Vardi, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema

W. Lumry, J. Schranz, H. Li, 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.

W. Lumry, M. Maurer, H. Longhurst, 2014, Allergy and asthma proceedings.

Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.

W. Lumry, T. Craig, S. Hurwitz, 2017, The journal of allergy and clinical immunology. In practice.

Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.

J. Bernstein, W. Lumry, T. Craig, 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data.

J. Bernstein, W. Lumry, P. Busse, 2016, The journal of allergy and clinical immunology. In practice.

Sustained Response Following Acute Treatment Of Hereditary Angioedema Attacks With Recombinant Human C1 Esterase Inhibitor

J. Bernstein, W. Lumry, H. Farkas, 2014 .

Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks.

W. Lumry, M. White, H. Li, 2012, Allergy and asthma proceedings.

Pre-procedure Administration of C1 Esterase Inhibitor (Human) (Cinryze™) for the Prevention of Hereditary Angioedema (HAE) Attacks after Medical, Dental, or Surgical Procedures

W. Lumry, P. Busse, J. Baker, 2011 .

Hereditary angioedema from the patient's perspective: A follow-up patient survey.

J. Bernstein, W. Lumry, P. Busse, 2018, Allergy and asthma proceedings.

Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients.

J. Bernstein, W. Lumry, P. Busse, 2017, The journal of allergy and clinical immunology. In practice.

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies

W. Lumry, H. Farkas, P. Busse, 2018, BioDrugs.

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies

W. Lumry, H. Farkas, P. Busse, 2018, BioDrugs.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

P. Keith, T. Machnig, J. Bernstein, 2018, The journal of allergy and clinical immunology. In practice.

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

M. Triggiani, J. Bernstein, M. Gompels, 2018, Allergy.

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

William H. Yang, J. Bernstein, W. Lumry, 2023, The Lancet.

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

William H. Yang, P. Keith, W. Lumry, 2022, The Lancet.

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

T. Machnig, J. Bernstein, W. Lumry, 2019, Allergy, Asthma & Clinical Immunology.

Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.

T. Machnig, J. Bernstein, W. Lumry, 2019, The journal of allergy and clinical immunology. In practice.

Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneous (SC) Cinryze® (C1 inhibitor (C1 INH) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with Hereditary Angioedema (HAE)

S. Dychter, W. Lumry, S. Gelone, 2012 .

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

Development of a health-related quality of life instrument for patients with hereditary angioedema living in the United States.

W. Lumry, J. Overbey, P. Busse, 2019, The journal of allergy and clinical immunology. In practice.

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study

J. Bernstein, W. Lumry, M. Maurer, 2021, Allergy.

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial.

William H. Yang, J. Bernstein, H. Iocca, 2020, The Journal of allergy and clinical immunology.

Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry.

J. Bernstein, W. Lumry, P. Busse, 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

W. Lumry, H. Farkas, T. Craig, 2017 .

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study

W. Lumry, M. Maurer, H. Longhurst, 2020, Allergy.

Association Between Self-Reported Dental Hygiene Practices and Dental Procedure-Related Recurrent Angioedema Attacks in HAE Subjects: A Multi-Center Survey.

J. Bernstein, W. Lumry, P. Busse, 2020, The journal of allergy and clinical immunology. In practice.

Results From FAST-3: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Subcutaneous Icatibant in Patients with Acute Hereditary Angioedema (HAE) Attacks

W. Lumry, H. Farkas, M. Riedl, 2011 .

Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).

J. Bernstein, H. Iocca, W. Lumry, 2021, The journal of allergy and clinical immunology. In practice.

Gastrointestinal (GI) Adverse Events (AEs) Observed With Berotralstat (BCX7353) Treatment for Hereditary Angioedema (HAE) are Primarily Mild, Self-limited, and Diminish with Time on Treatment

J. Bernstein, H. Iocca, W. Lumry, 2020 .

P154 SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY

J. Bernstein, W. Lumry, S. Murray, 2019, Annals of Allergy, Asthma & Immunology.

Hereditary angioedema: Epidemiology and burden of disease.

W. Lumry, R. Settipane, 2020, Allergy and asthma proceedings.

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks

J. Bernstein, W. Lumry, M. Maurer, 2020, Allergy.

Subcutaneous Human C1-Inhibitor with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema: Results of a Randomized, Double-Blind, Dose-Ranging, Crossover Study

J. Bernstein, W. Lumry, M. Maurer, 2015 .

Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks.

W. Lumry, J. Dayno, D. Fitts, 2014, Allergy and asthma proceedings.

Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence

Todor A Popov, T. Zuberbier, N. Papadopoulos, 2020, Allergy.

Inhibition of Prekallikrein for Hereditary Angioedema.

J. Bernstein, W. Lumry, B. Baker, 2022, The New England journal of medicine.

Safety and Efficacy of Nanofiltered C1 Esterase Inhibitor (Human) (Cinryze™) for the Treatment of Laryngeal Attacks in Subjects with Hereditary Angioedema (HAE)

W. Lumry, P. Busse, M. Riedl, 2011 .

Interim Results of EDEMA2, a Multicenter, Open-label, Repeat-Dosing Study of Intravenous and Subcutaneous Administration of Ecallantide (DX-88) in Hereditary Angioedema

W. Lumry, B. Ritchie, T. Beck, 2006 .

P154 BEROTRALSTAT IMPROVES PATIENT-REPORTED QUALITY OF LIFE THROUGH 48 WEEKS IN THE PHASE 3 APEX-2 TRIAL

J. Bernstein, H. Iocca, W. Lumry, 2020 .

Efficacy and Safety of Long-Term Prophylaxis with C1 Inhibitor (C1INH) Concentrate in Patients with Hereditary Angioedema (HAE)

W. Lumry, P. Busse, D. Tanner, 2008 .

Hereditary angioedema: a case of near fatal laryngeal swelling in a 41-year-old woman.

W. Lumry, 2011, Allergy and asthma proceedings.

Sinus headache: a neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatment.

M. Setzen, R. Cady, H. Levine, 2005, Mayo Clinic proceedings.

Omalizumab is effective in the long-term control of severe allergic asthma.

W. Lumry, J. Corren, B. Lanier, 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.

R. Pauwels, J. Bousquet, M. Kowalski, 2002, American journal of respiratory and critical care medicine.

A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.

W. Lumry, G. Della Cioppa, G. Bensch, 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis.

W. Lumry, R. Anolik, W. Lumry, 2009, Journal of investigational allergology & clinical immunology.

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

J. Church, W. Lumry, R. Wasserman, 2012, Journal of Clinical Immunology.

Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma.

W. Lumry, C. Reisner, R. Noveck, 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Evaluation of the ocular safety associated with the exhalation delivery system with fluticasone.

E. Meltzer, W. Lumry, David Skoner, 2021, Allergy and asthma proceedings.

Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.

I. Hussain, W. Lumry, J. Sleasman, 2019, Immunotherapy.

Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma.

E. Kerwin, W. Lumry, T. Craig, 2007, Respiratory medicine.

Ipratropium Bromide Nasal Spray * 0.03% Provides Additional Relief from Rhinorrhea When Combined With Terfenadine # in Perennial Rhinitis Patients; A Randomized, Double-Blind, Active-Controlled Trial

S. Spector, G. Settipane, P. Korenblat, 1998, American journal of rhinology.

Triamcinolone acetonide Aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study.

G. Settipane, W. Lumry, J. Winder, 1995, Clinical therapeutics.

Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data.

Lee Stern, J. Doyle, W. Lumry, 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis.

C. Caracta, W. Lumry, B. Prenner, 2019, Allergy and asthma proceedings.

Effect of once-daily desloratadine in patients with perennial allergic rhinitis (PAR): A double-blind, placebo-controlled study

W. Lumry, J. Hébert, D. Gates, 2003 .

Hypersensitivity Reactions to Ecallantide: an Update of the Clinical Trial Experience and Post-Market Surveillance for Treatment of Attacks of Hereditary Angioedema

J. Bernstein, W. Lumry, T. Craig, 2012 .

Efficacy and Safety of Azelastine 0.15% Nasal Spray and Azelastine 0.10% Nasal Spray in Patients with Seasonal Allergic Rhinitis

W. Lumry, W. Berger, H. Sacks, 2009, Allergy and asthma proceedings.

Budesonide turbuhaler delivered once daily improves health-related quality of life in adult patients with non-steroid-dependent asthma.

B. Parasuraman, W. Lumry, B. Liljas, 2003, Allergy and Asthma Proceedings.

Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group

M. Triggiani, W. Aberer, R. Perricone, 2012, Allergy.

Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis

R. Lockey, J. Biedenkapp, J. Bernstein, 2017, The New England journal of medicine.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

William H. Yang, P. Keith, P. Schmid‐Grendelmeier, 2010, The New England journal of medicine.

Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis.

R. Dockhorn, R. Lockey, W. Lumry, 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial.

W. Lumry, E. Aygören‐Pürsün, R. Tachdjian, 2023, The journal of allergy and clinical immunology. In practice.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.

W. Lumry, E. Aygören‐Pürsün, A. Reshef, 2024, The Lancet. Haematology.

Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis

W. Lumry, R. Tachdjian, M. Riedl, 2023, Allergy, Asthma & Clinical Immunology.

Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema.

W. Lumry, 2017, Immunology and allergy clinics of North America.